MPO33

MPO33, also known as MPO-33, is a chemical compound with the molecular formula C10H14N2O3S. It is a derivative of the drug methamphetamine, specifically a methoxylated analog. MPO33 was first synthesized in the early 2000s and has since gained attention in the scientific community due to its potential as a research tool in neuroscience.

The primary interest in MPO33 lies in its ability to selectively inhibit the dopamine transporter (DAT), a protein responsible for reuptaking dopamine from the synaptic cleft. This selective inhibition allows researchers to study the effects of increased dopamine levels in the brain, which is relevant to understanding the mechanisms behind various neurological disorders and behaviors.

MPO33 has been used in preclinical studies to investigate the role of dopamine in conditions such as Parkinson's disease, schizophrenia, and addiction. Its selective action on the DAT makes it a valuable tool for studying the dopamine system without the non-specific effects often associated with other dopamine transporter inhibitors.

However, it is important to note that MPO33 is not approved for human use and its administration should be strictly controlled due to its potential for abuse and the risks associated with its use in research settings. The synthesis and handling of MPO33 require adherence to strict regulatory guidelines to ensure safety and prevent misuse.

In summary, MPO33 is a methoxylated analog of methamphetamine that selectively inhibits the dopamine transporter. It is primarily used as a research tool in neuroscience to study the role of dopamine in various neurological conditions. Its use is subject to strict control due to potential risks and the need for adherence to regulatory guidelines.